Pentixapharm Holding AG (ETR:PTP) | Finanzwire

Basculer en Français

9473	Companies
185399	Keywords
117755	Articles
99281	Press releases

Headlines Articles Press releases Pentixapharm Holding AG

Home
Companies
Pentixapharm Holding AG

BRIEF

published on 10/23/2025 at 21:04, 1 month 12 days ago

Pentixapharm Shifts Focus to Clinical Advancement and Strengthens Finances

Financial Strategy Radiopharmaceuticals Clinical Programs Workforce Reduction Pentixapharm
PRESS RELEASE

published on 10/23/2025 at 20:59, 1 month 12 days ago

EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm Focuses Development on Advanced Clinical Programs and Strengthens Financial Position by Discontinuing Preclinical Activities
Pentixapharm Holding AG strengthens financial position by focusing on advanced clinical programs and discontinuing preclinical activities, reducing costs and extending cash runway

Financial Position Cost Reduction Clinical Programs Pentixapharm Preclinical Activities
BRIEF

published on 10/06/2025 at 11:05, 1 month 29 days ago

Pentixapharm Unveils Promising CXCR4 Radiopharmaceutical Data at EANM 2025

Bladder Cancer Treatment CXCR4 Radiopharmaceuticals Primary Aldosteronism Diagnostics EANM 2025 Conference Pentixapharm Innovations
PRESS RELEASE

published on 10/06/2025 at 11:00, 1 month 29 days ago

Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025
Pentixapharm presents new clinical findings on expanding CXCR4 radiopharmaceutical platform at EANM 2025, demonstrating potential in diagnosis and therapeutics in Primary Aldosteronism and bladder cancer

Pentixapharm CXCR4 Radiopharmaceutical EANM 2025 Clinical Findings
BRIEF

published on 09/26/2025 at 08:05, 2 months 9 days ago

Pentixapharm Advances PentixaTher in AML Trial

Clinical Trial Radiopharmaceuticals Acute Myeloid Leukemia PentixaTher CXCR4-targeting
PRESS RELEASE

published on 09/26/2025 at 08:00, 2 months 9 days ago

Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acute Myeloid Leukemia Trial
Pentixapharm advances PentixaTher to fourth dose level in AML trial, reinforcing safety profile and potential clinical efficacy for CXCR4-targeted radiotherapeutic in high unmet need indication

Pentixapharm CXCR4 Acute Myeloid Leukemia Radiotherapeutic PentixaTher
BRIEF

published on 05/27/2025 at 09:48, 6 months 8 days ago

Pentixapharm Unveils New Clinical Development Strategy

Oncology Pentixapharm CXCR4 Trials Theranostic Strategy Hematologic Malignancies
PRESS RELEASE

published on 05/27/2025 at 09:43, 6 months 8 days ago

EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy
Pentixapharm outlines new clinical development strategy focusing on CXCR4 therapeutic and diagnostic oncology programs, discontinuing PTF301 trial in MZL, preparing new trials in hematologic malignancies and Bladder Cancer

Pentixapharm CXCR4 Oncology Programs Clinical Development Strategy Theranostic Precision
BRIEF

published on 04/25/2025 at 15:44, 7 months 9 days ago

Pentixapharm to Showcase Innovative Antibody GT-008 at AACR 2025

Cancer Therapy Pentixapharm GT-008 Antibody Glycan-Dependent CD24 Targeting
PRESS RELEASE

published on 04/25/2025 at 15:39, 7 months 9 days ago

Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025
Pentixapharm to present novel CD24 antibody GT-008 for solid tumors at AACR 2025, showcasing glycan-dependent mechanism for targeted therapy

Solid Tumors Pentixapharm AACR 2025 GT-008 CD24 Antibody

Accesswire

Published on 12/05/2025 at 02:35, 6 hours 17 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 6 hours 22 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 7 hours 52 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 9 hours 47 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 9 hours 52 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 08:30, 22 minutes ago

Dahua Technology Celebrates Pro Challenge 2025 to Deepen Global Installer Ecosystem Collaboration
Published on 12/05/2025 at 08:30, 22 minutes ago

Premier Miton Global Renewables Trust PLC - Suspension
Published on 12/05/2025 at 08:05, 47 minutes ago

Smartmi Unveils the Air Purifier 3: Powerful, Smart, and Stylish Air Care for Modern Homes
Published on 12/05/2025 at 08:01, 51 minutes ago

Original-Research: Warimpex Finanz- und Beteiligungsholding AG (von East Value Research GmbH ):
Published on 12/05/2025 at 08:01, 51 minutes ago

Custodian Property Income REIT plc: Interim results for the period ended 30 September 2025

Les Echos

Published on 12/05/2025 at 08:45, 7 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 14 hours 52 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 15 hours 7 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 15 hours 8 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 1 hour ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE